PET & PET-CT
The San is one of the leading facilities offering PET and PET-CT scanning to patients across the Sydney region. Our recently opened state-of-the art facilities on the North Shore allow the San Radiology & Nuclear Medicine (SRNM) team of skilled imaging specialists to utilise the latest PET and PET-CT technologies to diagnose a range of conditions and assist with ongoing treatments.
PET stands for "positron emission tomography". It is a nuclear medicine imaging test in which a small amount of liquid radioactive material is injected into the body and is used to diagnose a variety of diseases, including many types of cancers, and brain and heart disease.
PET scanners are combined with computed tomography (CT) scanners, called PET-CT scanners. CT imaging uses X-ray equipment to create detailed images of slices of the inside of your body. The PET-CT combination allows any abnormality on the PET scan to be precisely located within the body, allowing for more accurate diagnosis of any problems. The PET or PET-CT scanner looks like a large box with a circular hole in the middle.
The radioactive substance most commonly used in PET scanning is a simple sugar (like glucose) called FDG, which stands for "fluorodeoxyglucose". It is injected into the bloodstream and accumulates in the body where it gives off energy in the form of gamma rays. These are detected by the PET scanner and a computer converts the signals into detailed pictures or images showing how tissue and organs are working. If you are having an FDG-PET, your sugar metabolism (how sugar is used by your body) is imaged. This is commonly used for cancer imaging, as the cancer cells need sugar to grow. FDG is also useful for imaging inflammatory or infective processes, and for imaging brain metabolism.
PET & PET-CT scans we perform
San Radiology & Nuclear Medicine provides a comprehensive PET imaging service utilising a range of tracers to maximise diagnostic sensitivity and specificity to diagnose, stage and monitor mostly cancers and neurodegenerative diseases.
F-18 FDG (Fluorodeoxyglucose)
- used to detect a broad range of cancers. The uptake of F-18 FDG by tissues is a marker for tissue uptake of glucose, with increased uptake seen in tissues with high metabolic activity such as most tumours
F-18 PSMA (DCFPyL or 1007)
- F-18 based tracer used to detect prostate cancer recurrent or metastatic lesions
- the ability to detect early metastatic deposits and early prostate cancer recurrence is very relevant for staging, prognosis and planning therapies
Ga-68 PSMA (Prostate Specific Membrane Antigen)
- Ga-68 based tracer used to detect prostate cancer recurrent or metastatic lesions with higher sensitivity than other imaging examinations
- the ability to detect early metastatic deposits and early prostate cancer recurrence is very relevant for staging, prognosis and planning therapies
Ga-68 DOTA-TATE
- used to detect somatostatin-avid malignancies such as Neuroendocrine Tumours (NET’s)
F-18- FET (Fluoroethyl-tyrosine)
- F-18 based tracer that plays a role in the detection of brain tumours, particularly tumour recurrence, and plays an important role in therapy planning, prognosis and management
F-18 - FBB (Florbetaben)
- F-18 based tracer that has a high level of sensitivity to identify and quantify beta-amyloid plaque accumulation in the brain, which is relevant to patients with persistent or progressive mild cognitive impairment who meet the criteria for possible Alzheimer’s disease or with progressive or atypical early onset dementia.